Immune Persistence and Safety Survey (Cohort Survey) related to the Bivalent SARS-CoV-2 Booster Vaccination in Japa
Not Applicable
- Conditions
- COVID-19
- Registration Number
- JPRN-UMIN000049533
- Lead Sponsor
- Juntendo University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 2848
Inclusion Criteria
Not provided
Exclusion Criteria
Those who are inappropriate as the subject of the survey determined by the principal investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety up to 4 weeks after the bivalent SARS-CoV-2 booster vaccination
- Secondary Outcome Measures
Name Time Method 1) Breakthrough infection rate up to 12 months after the bivalent SARS-CoV-2 booster vaccination 2) Serious adverse events up to 12 months after the bivalent SARS-CoV-2 vaccine (regardless of causality) 3) Changes in COVID-19 antibody titer up to 12 months after inoculation (part of the survey subjects) This may not be investigated if booster is given before 12 months